Business Description
Legend Biotech Corp
NAICS : 541714
SIC : 2834
ISIN : US52490G1022
Share Class Description:
FRA:9LB: ADRDescription
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.5 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | -1.15 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 5.37 | |||||
| Beneish M-Score | -1.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36.6 | |||||
| 3-Year EBITDA Growth Rate | -2.5 | |||||
| 3-Year EPS without NRI Growth Rate | -2.8 | |||||
| 3-Year FCF Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | 15.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 75.16 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.74 | |||||
| 9-Day RSI | 23.8 | |||||
| 14-Day RSI | 30.52 | |||||
| 3-1 Month Momentum % | -17.54 | |||||
| 6-1 Month Momentum % | -10.9 | |||||
| 12-1 Month Momentum % | -34.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.98 | |||||
| Quick Ratio | 4.9 | |||||
| Cash Ratio | 4.48 | |||||
| Days Inventory | 38.56 | |||||
| Days Sales Outstanding | 16.44 | |||||
| Days Payable | 53.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 | |||||
| Shareholder Yield % | -0.42 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.88 | |||||
| Operating Margin % | -67.03 | |||||
| Net Margin % | -66.92 | |||||
| FCF Margin % | -33.62 | |||||
| ROE % | -28.87 | |||||
| ROA % | -19.35 | |||||
| ROIC % | -84.66 | |||||
| 3-Year ROIIC % | -87.3 | |||||
| ROC (Joel Greenblatt) % | -164.16 | |||||
| ROCE % | -20.74 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.46 | |||||
| PB Ratio | 5.83 | |||||
| Price-to-Tangible-Book | 6.91 | |||||
| EV-to-EBIT | -17.46 | |||||
| EV-to-Forward-EBIT | 161.27 | |||||
| EV-to-EBITDA | -18.73 | |||||
| EV-to-Forward-EBITDA | 125.4 | |||||
| EV-to-Revenue | 10.84 | |||||
| EV-to-Forward-Revenue | 5.05 | |||||
| EV-to-FCF | -32.04 | |||||
| Price-to-GF-Value | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 8.92 | |||||
| Price-to-Net-Cash | 10.97 | |||||
| Earnings Yield (Greenblatt) % | -5.72 | |||||
| FCF Yield % | -2.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Legend Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 476.965 | ||
| EPS (TTM) (€) | -1.752 | ||
| Beta | -0.01 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.13 | ||
| Volatility % | 48.62 | ||
| 14-Day RSI | 30.52 | ||
| 14-Day ATR (€) | 1.418265 | ||
| 20-Day SMA (€) | 38.2 | ||
| 12-1 Month Momentum % | -34.04 | ||
| 52-Week Range (€) | 33.6 - 64.5 | ||
| Shares Outstanding (Mil) | 183.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Legend Biotech Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Legend Biotech Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Legend Biotech Corp Frequently Asked Questions
What is Legend Biotech Corp(FRA:9LB)'s stock price today?
The current price of FRA:9LB is €33.40. The 52 week high of FRA:9LB is €64.50 and 52 week low is €33.60.
When is next earnings date of Legend Biotech Corp(FRA:9LB)?
The next earnings date of Legend Biotech Corp(FRA:9LB) is 2025-03-11 Est..
Does Legend Biotech Corp(FRA:9LB) pay dividends? If so, how much?
Legend Biotech Corp(FRA:9LB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers